| abstract |
A derivative of formula I and pharmaceutically acceptable salts and solvates; where R.sup.1.n. is hydrogen, C 1-6-6 alkyl (optionally substituted with hydroxy or C 1-4-4 alkoxy), phenyl-C 1-4-4 alkyl-, C 1-4 alkyl. sub-1-6.n.alkenyl or C.sub.1-6.n.alkynyl; R.sup.2.n. is hydrogen or up to 3 substituents selected from halogen, NO 2, CN, N 3, CF 3, O-, CF 3, S-, CF. sub.3.n.SO.sub.2.n.-, CF.sub.3.n.CO-, C.sub.1-6.n.alkyl, C.sub.1-6.n.alkenyl C 1-6-6 alkynyl, C 1-6-6 perfluoroalkyl, C 3-6-6 cycloalkyl, C 3-6-6 cycloalkyl-C (1-4C) alkyl-, (C.sub.1-6.n.alkyl) O-, (C.sub.1-6.n.alkyl) CO-, (C.sub.1-6.n.alkyl) -6.n.cycloalkyl) O-, (C 3-8-6.n-cycloalkyl) CO-, (C 3-8-6.n-cycloalkyl-C 1-8-4.n-alkyl) O-, (C 3-6-6.cycloalkyl-C 1-4-4.n.alkyl) CO-, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C 1-4-4. n-alkyl-, (C 1-6-6. alkyl) S-, (C 1-8-6. alkyl) SO.sub.2.n.-, (C 1-8. -4.n.alkyl) .sub.2.n.sub.2.n.-, (C.sub.1-4.n.alkyl) NHSO.sub.2.n.-, (C.sub.1-4.n.alkyl). sub-1-4.n.alkyl) .sub.2.n.NCO-, (C.sub.1-4.n.alkyl) NHCO- or CONH.sub.2.n., or -NR.sup. .5.nRsup.6.n., Where R.sup.5.n. is hydrogen or C 1-4 alkyl, and R 6-6. is hydrogen, C 1-4 alkyl, formyl, C 1-4 alkyl or C 1-4 alkyl; or two R.sup.2.n. the groups together form a carbocyclic ring which is saturated or unsaturated, optionally interrupted by O or NH; R.sup.3.n. and R.sup.4.n. the groups are independently hydrogen or C 1-6-6 alkyl and / or two R 3-6 alkyl groups. groups and / or two R.sup.4.n. the groups together form C.sub.3-6.n. a spiroalkyl group provided that at least one of R.sup.3.n. or R.sup.4.n. is not hydrogen; and X is selected from hydrogen |